Hereditary angioedema:

Indications for: BERINERT

Treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in adult and pediatric patients.

Limitations of Use:

Safety and efficacy for prophylactic therapy have not been established.

Adults and Children:

Give 20 IU/kg by slow IV inj at a rate of approx. 4mL/min. Do not administer doses <20 IU/kg.

BERINERT Warnings/Precautions:

Discontinue immediately if hypersensitivity reactions are suspected. Have epinephrine inj available. Monitor patients with known risk factors for thromboembolic events (eg, indwelling venous catheter/access device, history of thrombosis, atherosclerosis, morbid obesity, immobility). Contains human plasma; monitor for possible infection transmission (eg, viruses, Creutzfeldt-Jakob disease agent). Pregnancy. Nursing mothers.

BERINERT Classification:

C1 inhibitor.

BERINERT Interactions:

Risk of thrombotic events with concomitant oral contraceptives or certain androgens.

Adverse Reactions:

Dysgeusia, increased severity of pain; hypersensitivity reactions, thromboembolic events.


To report infections that may have been transmitted by Berinert, call the CSL Behring Pharmacovigilance Department at (866) 915-6958.

Generic Drug Availability:


How Supplied:

Single-use vial—1 (w. supplies)